Humacyte to present interim Phase 3 V012 trial results for ATEV in women on dialysis

Humacyte to present interim Phase 3 V012 trial results for ATEV in women on dialysis
Humacyte reveals Phase 3 ATEV data

Humacyte will present interim results from its Phase 3 V012 clinical trial evaluating ATEV for hemodialysis access in women. The announcement highlights that women on dialysis are more likely to face fistula failure and catheter dependence compared to men.

The company is scheduled to share its data at Kidney Week on Thursday, October 22 at 4:40 PM MT. The trial focuses on alternative solutions for vascular access among female dialysis patients where current failure rates remain high.

Humacyte previously announced plans to present Phase 3 ATEV trial results for women needing hemodialysis access at ASN Kidney Week 2026, according to a recent update. The company also recently completed its first commercial Symvess procedure in Florida at Sacred Heart Emerald Coast, expanding its product availability as reported earlier this year. These developments follow ongoing efforts to address vascular access challenges in dialysis patients.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.